Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
46.58B
Cash
1.986B
Avg Qtr Burn
N/A
Short % of Float
0.64%
Insider Ownership
0.14%
Institutional Own.
66.66%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution) Details Intra-ocular pressure, Opthalmolgy, Eye disease | Approved Quarterly sales | |
Approved Quarterly sales | ||
AR-1105 Details Eye disease , Diabetic macular edema, Diabetes | Phase 3 Update | |
AR-15512 (TRPM8 agonist eye drop) Details Eye disease , Dry eye syndrome, Opthalmolgy, Metastatic merkel cell carcinoma | Phase 3 Update |